MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/fjc.0000000000001600

Медицинская библиотека · Journal of cardiovascular pharmacology · 2025

The Potential Impact of Renin-Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis.

Fatima Kaneez, Ellahi Aayat, Adil Mariam, Kashif Haider, Uzair Muhammad, Ashraf Naela, Barolia Mehak, Hyder Mujtaba, Nakhuda Areeba, Ayub Michelle, Butt Sofia Jamil, Rashid Ahmed Mustafa

СтатьяМетаанализСистематический обзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Renin-angiotensin system inhibitors (RASis), specifically angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), are widely used antihypertensives. Their impact on the prognostic outcomes among patients with cancer has been subject to scrutiny and debate. The aim of this study was to evaluate the effect of RASis on survival in patients with cancer.We systematically searched PubMed, Web of Science, Embase, and Cochrane Library for relevant studies published until April 1, 2022. All the studies, interventional or observational, which examined effects of ARBs and ACEis on cancer prognosis compared with a control group and reported the survival outcomes and hazard ratios were included in the analysis. From each study, pooled hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were identified and collected. Subgroup analysis was conducted to investigate heterogeneity.61 studies were included in this meta-analysis. Data of 343,283 participants were used in the study. It was found that RASis improved overall survival (HR = 0.88; 95% CI, 0.82-0.93; P < 0.0001), progression-free survival (HR = 0.72; 95% CI, 0.65-0.79; P < 0.00001), disease-specific survival (HR = 0.86; 95% CI, 0.71-1.04; P = 0.03), and recurrence-free survival (HR = 0.74; 95% CI, 0.58-0.93; P = 0.01) in patients with cancer. The effect of RASis on overall survival varied depending on the type of cancer or type of RASis (ACEis or ARBs), according to subgroup analysis.The usage of renin-angiotensin system inhibitors has a positive impact on survival outcomes and recurrence among patients with cancer.

Для цитирования: Fatima Kaneez, Ellahi Aayat, Adil Mariam, Kashif Haider, Uzair Muhammad, Ashraf Naela, Barolia Mehak, Hyder Mujtaba, Nakhuda Areeba, Ayub Michelle, Butt Sofia Jamil, Rashid Ahmed Mustafa. The Potential Impact of Renin-Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis.. Journal of cardiovascular pharmacology. 2025. DOI: 10.1097/fjc.0000000000001600.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.